PMN vs. RGLS, RNAC, FGEN, CRVS, SCPH, ALLK, OPTN, KPTI, ACET, and CTXR
Should you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Regulus Therapeutics (RGLS), Cartesian Therapeutics (RNAC), FibroGen (FGEN), Corvus Pharmaceuticals (CRVS), scPharmaceuticals (SCPH), Allakos (ALLK), OptiNose (OPTN), Karyopharm Therapeutics (KPTI), Adicet Bio (ACET), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical preparations" industry.
ProMIS Neurosciences (NASDAQ:PMN) and Regulus Therapeutics (NASDAQ:RGLS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
ProMIS Neurosciences has higher revenue and earnings than Regulus Therapeutics. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Regulus Therapeutics, indicating that it is currently the more affordable of the two stocks.
Regulus Therapeutics' return on equity of -65.69% beat ProMIS Neurosciences' return on equity.
In the previous week, Regulus Therapeutics had 2 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 3 mentions for Regulus Therapeutics and 1 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 1.89 beat Regulus Therapeutics' score of 1.30 indicating that ProMIS Neurosciences is being referred to more favorably in the media.
ProMIS Neurosciences has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500.
Regulus Therapeutics received 479 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 63.54% of users gave Regulus Therapeutics an outperform vote.
ProMIS Neurosciences currently has a consensus price target of $8.00, indicating a potential upside of 334.31%. Regulus Therapeutics has a consensus price target of $7.25, indicating a potential upside of 216.59%. Given ProMIS Neurosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe ProMIS Neurosciences is more favorable than Regulus Therapeutics.
50.1% of ProMIS Neurosciences shares are owned by institutional investors. Comparatively, 92.4% of Regulus Therapeutics shares are owned by institutional investors. 6.4% of ProMIS Neurosciences shares are owned by insiders. Comparatively, 4.4% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
ProMIS Neurosciences and Regulus Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get ProMIS Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProMIS Neurosciences Competitors List
Related Companies and Tools
